{"id":"aflibercept","rwe":[{"pmid":"41905242","year":"2026","title":"Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629).","finding":"","journal":"European journal of cancer (Oxford, England : 1990)","studyType":"Clinical Study"},{"pmid":"41904245","year":"2026","title":"Long term evolutions of hard exudates after anti-VEGF therapy for diabetic macular oedema.","finding":"","journal":"Eye (London, England)","studyType":"Clinical Study"},{"pmid":"41903075","year":"2026","title":"Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.","finding":"","journal":"Ophthalmology and therapy","studyType":"Clinical Study"},{"pmid":"41902887","year":"2026","title":"Use of Aflibercept 8 mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison.","finding":"","journal":"Advances in therapy","studyType":"Clinical Study"},{"pmid":"41899134","year":"2026","title":"Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"}],"_fda":{"id":"42277606-719f-1fd3-e063-6394a90ad9d6","set_id":"289e4b90-f741-c0f6-e063-6394a90a2068","openfda":{"unii":["15C2VL427D"],"route":["INTRAVITREAL"],"rxcui":["2706533","2706541"],"spl_id":["42277606-719f-1fd3-e063-6394a90ad9d6"],"brand_name":["AHZANTIVE"],"spl_set_id":["289e4b90-f741-c0f6-e063-6394a90a2068"],"package_ndc":["85006-2908-1"],"product_ndc":["85006-2908"],"generic_name":["AFLIBERCEPT-MRBB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AFLIBERCEPT-MRBB"],"manufacturer_name":["Valorum Biologics, LLC"],"application_number":["BLA761378"],"is_original_packager":[true]},"version":"7","overdosage":["10 OVERDOSAGE Overdosing with increased injection volume may increase intraocular pressure. Therefore, in case of overdosage, intraocular pressure should be monitored and if deemed necessary by the treating physician, adequate treatment should be initiated."],"description":["11 DESCRIPTION Aflibercept-mrbb is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept-mrbb is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept-mrbb is produced in recombinant Chinese hamster ovary (CHO) cells. AHZANTIVE (aflibercept-mrbb) injection is a sterile, clear, and colorless to pale yellow solution. AHZANTIVE does not contain anti-microbial preservative and is supplied as a sterile, aqueous solution for intravitreal injection in a single-dose glass vial designed to deliver 0.05 mL (50 microliters) of solution containing 2 mg of aflibercept-mrbb in histidine (0.046 mg), L‑histidine hydrochloride monohydrate (0.043 mg), polysorbate 20 (0.015 mg), sodium chloride (0.117 mg), sucrose (2.5 mg) and water for injection with a pH of 6.2."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Each pre-filled syringe or vial is for single eye use only. Discard unused portion. AHZANTIVE (aflibercept-mrbb) injection is a clear, colorless to pale yellow solution and is supplied in the following presentation [see Dosage and Administration (2.1), (2.6), (2.7) and (2.8)]. NDC Number Carton Type Carton Contents 85006-8092-1 Pre-filled Syringe one blister pack containing one AHZANTIVE 2 mg (0.05 mL of a 40 mg/mL solution) sterile, single‑dose pre-filled syringe one Prescribing Information 85006-2908-1 Vial Only one AHZANTIVE 2 mg (0.05 mL of a 40 mg/mL solution) single-dose glass vial one Prescribing Information The AHZANTIVE pre-filled syringe cap and plunger are not made with natural rubber latex. The AHZANTIVE vial stopper is not made with natural rubber latex. 16.2 Storage and Handling Refrigerate AHZANTIVE at 2°C to 8ºC (36°F to 46ºF). Do not freeze. Do not use beyond the date stamped on the carton and container label. Store in the original carton until time of use to protect from light."],"effective_time":"20251027","clinical_studies":["14 CLINICAL STUDIES 14.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) The safety and efficacy of aflibercept were assessed in two randomized, multi-center, double-masked, active-controlled studies in patients with wet AMD. A total of 2412 patients were treated and evaluable for efficacy (1817 with aflibercept) in the two studies (VIEW1 and VIEW2). In each study, up to week 52, patients were randomly assigned in a 1:1:1:1 ratio to 1 of 4 dosing regimens: 1) aflibercept administered 2 mg every 8 weeks following 3 initial monthly doses (aflibercept 2Q8); 2) aflibercept administered 2 mg every 4 weeks (aflibercept 2Q4); 3) aflibercept 0.5 mg administered every 4 weeks (aflibercept 0.5Q4); and 4) ranibizumab administered 0.5 mg every 4 weeks (ranibizumab 0.5 mg Q4). Protocol-specified visits occurred every 28±3 days. Patient ages ranged from 49 to 99 years with a mean of 76 years. In both studies, the primary efficacy endpoint was the proportion of patients who maintained vision, defined as losing fewer than 15 letters of visual acuity at week 52 compared to baseline. Both aflibercept 2Q8 and aflibercept 2Q4 groups were shown to have efficacy that was clinically equivalent to the ranibizumab 0.5 mg Q4 group in year 1. Detailed results from the analysis of the VIEW1 and VIEW2 studies are shown in Table 4 and Figure 13 below. Table 4: Efficacy Outcomes at Week 52 (Full Analysis Set with LOCF) in VIEW1 and VIEW2 Studies VIEW 1 VIEW 2 Aflibercept 2 mg Q8 weeks a Aflibercept 2 mg Q4 weeks ranibizu-mab 0.5 mg Q4 weeks Aflibercept 2 mg Q8 weeks a Aflibercept 2 mg Q4 weeks ranibizu-mab 0.5 mg Q4 weeks N=301 N=304 N=304 N=306 N=309 N=291 Efficacy Outcomes Proportion of patients who maintained visual acuity (%) (<15 letters of BCVA loss) 94% 95% 94% 95% 95% 95% Differenceb (%) (95.1% CI) 0.6 (-3.2, 4.4) 1.3 (-2.4, 5.0) 0.6 (-2.9, 4.0) -0.3 (-4.0, 3.3) Mean change in BCVA as measured by ETDRS letter score from Baseline 7.9 10.9 8.1 8.9 7.6 9.4 Difference b in LS mean (95.1% CI) 0.3 (-2.0, 2.5) 3.2 (0.9, 5.4) -0.9 (-3.1, 1.3) -2.0 (-4.1, 0.2) Number of patients who gained at least 15 letters of vision from Baseline (%) 92 (31%) 114 (38%) 94 (31%) 96 (31%) 91 (29%) 99 (34%) Differenceb (%) (95.1% CI) -0.4 (-7.7, 7.0) 6.6 (-1.0, 14.1) -2.6 (-10.2, 4.9) -4.6 (-12.1, 2.9) BCVA = Best Corrected Visual Acuity; CI = Confidence Interval; ETDRS = Early Treatment Diabetic Retinopathy Study; LOCF = Last Observation Carried Forward (baseline values are not carried forward); 95.1% confidence intervals were presented to adjust for safety assessment conducted during the study a After treatment initiation with 3 monthly doses b Aflibercept group minus the ranibizumab group Treatment effects in evaluable subgroups (e.g., age, gender, race, baseline visual acuity) in each study were in general consistent with the results in the overall populations. Figure 13: Mean Change in Visual Acuity from Baseline to Week 96* in VIEW1 and VIEW2 Studies *Patient dosing schedules were individualized from weeks 52 to 96 using a modified 12-week dosing regimen. VIEW1 and VIEW2 studies were both 96 weeks in duration. However after 52 weeks patients no longer followed a fixed dosing schedule. Between week 52 and week 96, patients continued to receive the drug and dosage strength to which they were initially randomized on a modified 12 week dosing schedule (doses at least every 12 weeks and additional doses as needed). Therefore, during the second year of these studies there was no active control comparison arm. 14.2 Macular Edema Following Central Retinal Vein Occlusion (CRVO) The safety and efficacy of aflibercept were assessed in two randomized, multi-center, double-masked, sham-controlled studies in patients with macular edema following CRVO. A total of 358 patients were treated and evaluable for efficacy (217 with aflibercept) in the two studies (COPERNICUS and GALILEO). In both studies, patients were randomly assigned in a 3:2 ratio to either 2 mg aflibercept administered every 4 weeks (2Q4), or sham injections (control group) administered every 4 weeks for a total of 6 injections. Protocol-specified visits occurred every 28±7 days. Patient ages ranged from 22 to 89 years with a mean of 64 years. In both studies, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters in BCVA compared to baseline. At week 24, the aflibercept 2 mg Q4 group was superior to the control group for the primary endpoint. Results from the analysis of the COPERNICUS and GALILEO studies are shown in Table 5 and Figure 14 below. Table 5: Efficacy Outcomes at Week 24 (Full Analysis Set with LOCF) in COPERNICUS and GALILEO Studies COPERNICUS GALILEO Control Aflibercept 2 mg Q4 weeks Control Aflibercept 2 mg Q4 weeks N=73 N=114 N=68 N=103 Efficacy Outcomes Proportion of patients who gained at least 15 letters in BCVA from Baseline (%) 12% 56% 22% 60% Weighted Difference a, b (%) (95.1% CI) 44.8% c (32.9, 56.6) 38.3% c (24.4, 52.1) Mean change in BCVA as measured by ETDRS letter score from Baseline (SD) -4.0 (18.0) 17.3 (12.8) 3.3 (14.1) 18.0 (12.2) Difference in LS mean a, d (95.1% CI) 21.7c (17.3, 26.1) 14.7 c (10.7, 18.7) a Difference is Aflibercept 2 mg Q4 weeks minus Control b Difference and CI are calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for baseline factors; 95.1% confidence intervals were presented to adjust for the multiple assessments conducted during the study c p<0.01 compared with Control d LS mean and CI based on an ANCOVA model Figure 14: Mean Change in BCVA as Measured by ETDRS Letter Score from Baseline to Week 24 in COPERNICUS and GALILEO Studies Treatment effects in evaluable subgroups (e.g., age, gender, race, baseline visual acuity, retinal perfusion status, and CRVO duration) in each study and in the combined analysis were in general consistent with the results in the overall populations. 14.3 Macular Edema Following Branch Retinal Vein Occlusion (BRVO) The safety and efficacy of aflibercept were assessed in a 24-week, randomized, multi-center, double-masked, controlled study in patients with macular edema following BRVO. A total of 181 patients were treated and evaluable for efficacy (91 with aflibercept) in the VIBRANT study. In the study, patients were randomly assigned in a 1:1 ratio to either 2 mg aflibercept administered every 4 weeks (2Q4) or laser photocoagulation administered at baseline and subsequently as needed (control group). Protocol-specified visits occurred every 28±7 days. Patient ages ranged from 42 to 94 years with a mean of 65 years. In the VIBRANT study, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters in BCVA at week 24 compared to baseline. At week 24, the aflibercept 2 mg Q4 group was superior to the control group for the primary endpoint. Detailed results from the analysis of the VIBRANT study are shown in Table 6 and Figure 15 below. Table 6: Efficacy Outcomes at Week 24 (Full Analysis Set with LOCF) in VIBRANT Study VIBRANT Control Aflibercept 2 mg Q4 weeks N=90 N=91 Efficacy Outcomes Proportion of patients who gained at least 15 letters in BCVA from Baseline (%) 26.7% 52.7% Weighted Difference a, b (%) (95% CI) 26.6% c (13.0, 40.1) Mean change in BCVA as measured by ETDRS letter score from Baseline (SD) 6.9 (12.9) 17.0 (11.9) Difference in LS mean a, d (95% CI) 10.5 c (7.1, 14.0) a Difference is Aflibercept 2 mg Q4 weeks minus Control b Difference and CI are calculated using Mantel-Haenszel weighting scheme adjusted for region (North America vs. Japan) and baseline BCVA category (> 20/200 and ≤ 20/200) c p<0.01 compared with Control d LS mean and CI based on an ANCOVA model Figure 15: Mean Change in BCVA as Measured by ETDRS Letter Score from Baseline to Week 24 in VIBRANT Study Treatment effects in evaluable subgroups (e.g., age, gender, and baseline retinal perfusion status) in the study were in general consistent with the results in the overall populations. 14.4 Diabetic Macular Edema (DME) The safety and efficacy of aflibercept were assessed in two randomized, multi-center, double-masked, controlled studies in patients with DME. A total of 862 randomized and treated patients were evaluable for efficacy. Protocol-specified visits occurred every 28±7 days. Patient ages ranged from 23 to 87 years with a mean of 63 years. Of those, 576 were randomized to aflibercept groups in the two studies (VIVID and VISTA). In each study, patients were randomly assigned in a 1:1:1 ratio to 1 of 3 dosing regimens: 1) aflibercept administered 2 mg every 8 weeks following 5 initial monthly injections (aflibercept 2Q8); 2) aflibercept administered 2 mg every 4 weeks (aflibercept 2Q4); and 3) macular laser photocoagulation (at baseline and then as needed). Beginning at week 24, patients meeting a pre‑specified threshold of vision loss were eligible to receive additional treatment: patients in the aflibercept groups could receive laser and patients in the laser group could receive aflibercept. In both studies, the primary efficacy endpoint was the mean change from baseline in BCVA at week 52 as measured by ETDRS letter score. Efficacy of both aflibercept 2Q8 and aflibercept 2Q4 groups was statistically superior to the control group. This statistically superior improvement in BCVA was maintained at week 100 in both studies. Results from the analysis of the VIVID and VISTA studies are shown in Table 7 and Figure 16 below. Table 7: Efficacy Outcomes at Weeks 52 and 100 (Full Analysis Set with LOCF) in VIVID and VISTA Studies VIVID VISTA Aflibercept 2 mg Q8 weeks a Aflibercept 2 mg Q4 weeks Control Aflibercept 2 mg Q8 weeks a Aflibercept 2 mg Q4 weeks Control Full Analysis Set N=135 N=136 N=132 N=151 N=154 N=154 Efficacy Outcomes at Week 52 Mean change in BCVA as measured by ETDRS letter score from Baseline (SD) 10.7 (9.3) 10.5 (9.6) 1.2 (10.6) 10.7 (8.2) 12.5 (9.5) 0.2 (12.5) Difference b, c in LS mean (97.5% CI) 9.1 d (6.3, 11.8) 9.3 d (6.5, 12.0) 10.5 d (7.7, 13.2) 12.2 d (9.4, 15.0) Proportion of patients who gained at least 15 letters in BCVA from Baseline (%) 33.3% 32.4% 9.1% 31.1% 41.6% 7.8% Adjusted Difference c, e (%) (97.5% CI) 24.2 d (13.5, 34.9) 23.3 d (12.6, 33.9) 23.3 d (13.5, 33.1) 34.2 d (24.1, 44.4) Efficacy Outcomes at Week 100 Mean change in BCVA as measured by ETDRS letter score from Baseline (SD) 9.4 (10.5) 11.4 (11.2) 0.7 (11.8) 11.1 (10.7) 11.5 (13.8) 0.9 (13.9) Differenceb, c in LS mean (97.5% CI) 8.2d (5.2, 11.3) 10.7 d (7.6, 13.8) 10.1 d (7.0, 13.3) 10.6 d (7.1, 14.2) Proportion of patients who gained at least 15 letters in BCVA from Baseline (%) 31.1% 38.2% 12.1% 33.1% 38.3% 13.0% Adjusted Difference c, e (%) (97.5% CI) 19.0 d (8.0, 29.9) 26.1 d (14.8, 37.5) 20.1 d (9.6, 30.6) 25.8 d (15.1, 36.6) a After treatment initiation with 5 monthly injections b LS mean and CI based on an ANCOVA model with baseline BCVA measurement as a covariate and a factor for treatment group. Additionally, protocol specified stratification factors were included in the model c Difference is Aflibercept group minus Control group d p<0.01 compared with Control e Difference with confidence interval (CI) and statistical test is calculated using Mantel-Haenszel weighting scheme adjusted by protocol specified stratification factors Figure 16: Mean Change in BCVA as Measured by ETDRS Letter Score from Baseline to Week 100 in VIVID and VISTA Studies Treatment effects in the subgroup of patients who had previously been treated with a VEGF inhibitor prior to study participation were similar to those seen in patients who were VEGF inhibitor naïve prior to study participation. Treatment effects in evaluable subgroups (e.g., age, gender, race, baseline HbA1c, baseline visual acuity, prior anti-VEGF therapy) in each study were in general consistent with the results in the overall populations. 14.5 Diabetic Retinopathy (DR) Efficacy and safety data of aflibercept in diabetic retinopathy (DR) are derived from the VIVID, VISTA, and PANORAMA studies. VIVID AND VISTA In the VIVID and VISTA studies, an efficacy outcome was the change in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (ETDRS-DRSS). The ETDRS-DRSS score was assessed at baseline and approximately every 6 months thereafter for the duration of the studies [see Clinical Studies (14.4)]. All enrolled patients had DR and DME at baseline. The majority of patients enrolled in these studies (77%) had moderate-to-severe nonproliferative diabetic retinopathy (NPDR) based on the ETDRS-DRSS. At week 100, the proportion of patients improving by at least 2 steps on the ETDRS-DRSS was significantly greater in both aflibercept treatment groups (2Q4 and 2Q8) when compared to the control group. Results from the analysis of ETDRS-DRSS at week 100 in the VIVID and VISTA studies are shown in Table 8 below. Table 8: Proportion of Patients Who Achieved a ≥2-Step Improvement from Baseline in the ETDRS-DRSS Score at Week 100 in VIVID and VISTA Studies VIVID VISTA Aflibercept 2 mg Q8 weeks a Aflibercept 2 mg Q4 weeks Control Aflibercept 2 mg Q8 weeks a Aflibercept 2 mg Q4 weeks Control Evaluable Patients b N=101 N=97 N=99 N=148 N=153 N=150 Number of patients with a ≥2-step improvement on ETDRS-DRSS from Baseline (%) 32 (32%) 27 (28%) 7 (7%) 56 (38%) 58 (38%) 24 (16%) Difference c,d (%) (97.5% CI) 24% e (12, 36) 21% e (9, 33) 22% e (11, 33) 22% e (11, 33) Non-gradable post-baseline ETDRS-DRSS values were treated as missing and were imputed using the last gradable ETDRS-DRSS values (including baseline values if all post-baseline values were missing or non-gradable) a After treatment initiation with 5 monthly injections b The number of evaluable patients included all patients who had valid ETDRS-DRSS data at baseline c Difference with confidence interval (CI) was calculated using Mantel-Haenszel weighting scheme adjusted by protocol specified stratification factors d Difference is Aflibercept minus Control group e p<0.01 compared with Control Results of the evaluable subgroups (e.g., age, gender, race, baseline HbA1c, baseline visual acuity) on the proportion of patients who achieved a ≥2-step improvement on the ETDRS-DRSS from baseline to week 100 were, in general, consistent with those in the overall population. PANORAMA The PANORAMA study assessed the safety and efficacy of aflibercept in a randomized, multi-center, double-masked, controlled study in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) (ETDRS-DRSS of 47 or 53), without central-involved DME (CI-DME). A total of 402 randomized patients were evaluable for efficacy. Protocol-specified visits occurred every 28±7 days for the first 5 visits, then every 8 weeks (56±7 days). Patient ages ranged from 25 to 85 years with a mean of 55.7 years. Patients were randomly assigned in a 1:1:1 ratio to 1 of 3 dosing regimens: 1) 3 initial monthly aflibercept 2 mg injections followed by one injection after 8 weeks and then one injection every 16 weeks (aflibercept 2Q16); 2) 5 monthly aflibercept 2 mg injections followed by one injection every 8 weeks (aflibercept 2Q8); and 3) sham treatment. The primary efficacy endpoint was the proportion of patients who improved by ≥2 steps on the DRSS from baseline to week 24 in the combined aflibercept groups and at week 52 in the 2Q16 and 2Q8 groups individually versus sham. A key secondary endpoint was the proportion of patients developing the composite endpoint of proliferative diabetic retinopathy or anterior segment neovascularization through week 52. At week 52, efficacy in the 2Q16 and 2Q8 groups was superior to the sham group (see Table 9 and Table 10). The proportion of patients with a ≥2-step improvement over time is shown in Figure 17. Table 9: Proportion of Patients Who Achieved a ≥2-Step Improvement from Baseline in the ETDRS-DRSS Score at Weeks 24 and 52 in PANORAMA PANORAMA Week 24 Week 52 Aflibercept Combined Control (sham) Aflibercept 2Q16 Aflibercept 2Q8 Control (sham) Full Analysis Set N=269 N=133 N=135 N=134 N=133 Proportion of patients with a ≥2-step improvement on ETDRS-DRSS from Baseline (%) 58% 6% 65% 80% 15% Adjusted Difference a (%) (95% CI) b 52% c (45, 60) 50% c (40, 60) 65% c (56, 74) Non-gradable post-baseline ETDRS-DRSS values were treated as missing and were imputed using the last gradable ETDRS-DRSS values (including baseline values if all post-baseline values were missing or non-gradable) a Difference is Aflibercept group minus sham b Difference with CI was calculated using the Mantel-Haenszel weighting scheme adjusted by baseline DRSS stratification variable c p<0.01 compared with Control. p-value was calculated using a 2-sided Cochran-Mantel-Haenszel test adjusted by baseline DRSS stratification variable Figure 17: Proportion of Patients Who Achieved a ≥2-Step Improvement from Baseline in the ETDRS-DRSS Score Through Week 52 in PANORAMA Table 10: Effect of Aflibercept on Worsening of Diabetic Retinopathy in PANORAMA through Week 52 Aflibercept 2Q16 Aflibercept 2Q8 Control (sham) Full Analysis Set N=135 N=134 N=133 Composite Endpoint of Developing PDR or ASNV a Event Rate b 4.0% d 2.4% d 20.1% Hazard Ratio 0.15 0.12 Development of Proliferative Diabetic Retinopathy c Event Rate b 1.6% d 0.0% d 11.9% Hazard Ratio 0.11 0.00 PDR = Proliferative Diabetic Retinopathy; ASNV = Anterior Segment Neovascularization a As diagnosed by either the Reading Center or Investigator through week 52 b Estimated using Kaplan-Meier method c Defined as ≥2-step worsening on the ETDRS-DRSS score through week 52 d p<0.01 compared with Control 13 14 15 16 17"],"adverse_reactions":["6 ADVERSE REACTIONS The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4.3)] Endophthalmitis, Retinal Detachments, and Retinal Vasculitis with or without Occlusion [see Warnings and Precautions (5.1)] Increase in intraocular pressure [see Warnings and Precautions (5.2)] Thromboembolic events [see Warnings and Precautions (5.3)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice. A total of 2980 adult patients treated with aflibercept constituted the safety population in eight phase 3 studies. Among those, 2379 patients were treated with the recommended dose of 2 mg. Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with aflibercept including endophthalmitis and retinal detachment. The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased. Neovascular (Wet) Age-Related Macular Degeneration (AMD) The data described below reflect exposure to aflibercept in 1824 patients with wet AMD, including 1223 patients treated with the 2-mg dose, in 2 double-masked, controlled clinical studies (VIEW1 and VIEW2) for 24 months (with active control in year 1) [see Clinical Studies (14.1)]. Safety data observed in the aflibercept group in a 52-week, double-masked, Phase 2 study were consistent with these results. Table 1: Most Common Adverse Reactions (≥1%) in Wet AMD Studies Adverse Reactions Baseline to Week 52 Baseline to Week 96 Aflibercept (N=1824) Active Control (ranibizumab) (N=595) Aflibercept (N=1824) Control (ranibizumab) (N=595) Conjunctival hemorrhage 25% 28% 27% 30% Eye pain 9% 9% 10% 10% Cataract 7% 7% 13% 10% Vitreous detachment 6% 6% 8% 8% Vitreous floaters 6% 7% 8% 10% Intraocular pressure increased 5% 7% 7% 11% Ocular hyperemia 4% 8% 5% 10% Corneal epithelium defect 4% 5% 5% 6% Detachment of the retinal pigment epithelium 3% 3% 5% 5% Injection site pain 3% 3% 3% 4% Foreign body sensation in eyes 3% 4% 4% 4% Lacrimation increased 3% 1% 4% 2% Vision blurred 2% 2% 4% 3% Intraocular inflammation 2% 3% 3% 4% Retinal pigment epithelium tear 2% 1% 2% 2% Injection site hemorrhage 1% 2% 2% 2% Eyelid edema 1% 2% 2% 3% Corneal edema 1% 1% 1% 1% Retinal detachment <1% <1% 1% 1% Less common serious adverse reactions reported in <1% of the patients treated with aflibercept were hypersensitivity, retinal tear, and endophthalmitis. Macular Edema Following Retinal Vein Occlusion (RVO) The data described below reflect 6 months exposure to aflibercept with a monthly 2 mg dose in 218 patients following central retinal vein occlusion (CRVO) in 2 clinical studies (COPERNICUS and GALILEO) and 91 patients following branch retinal vein occlusion (BRVO) in one clinical study (VIBRANT) [see Clinical Studies (14.2), (14.3)]. Table 2: Most Common Adverse Reactions (≥1%) in RVO Studies Adverse Reactions CRVO BRVO Aflibercept (N=218) Control (N=142) Aflibercept (N=91) Control (N=92) Eye pain 13% 5% 4% 5% Conjunctival hemorrhage 12% 11% 20% 4% Intraocular pressure increased 8% 6% 2% 0% Corneal epithelium defect 5% 4% 2% 0% Vitreous floaters 5% 1% 1% 0% Ocular hyperemia 5% 3% 2% 2% Foreign body sensation in eyes 3% 5% 3% 0% Vitreous detachment 3% 4% 2% 0% Lacrimation increased 3% 4% 3% 0% Injection site pain 3% 1% 1% 0% Vision blurred 1% <1% 1% 1% Intraocular inflammation 1% 1% 0% 0% Cataract <1% 1% 5% 0% Eyelid edema <1% 1% 1% 0% Less common adverse reactions reported in <1% of the patients treated with aflibercept in the CRVO studies were corneal edema, retinal tear, hypersensitivity, and endophthalmitis. Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) The data described below reflect exposure to aflibercept in 578 patients with DME treated with the 2-mg dose in 2 double-masked, controlled clinical studies (VIVID and VISTA) from baseline to week 52 and from baseline to week 100 [see Clinical Studies (14.4)]. Table 3: Most Common Adverse Reactions (≥1%) in DME Studies Adverse Reactions Baseline to Week 52 Baseline to Week 100 Aflibercept (N=578) Control (N=287) Aflibercept (N=578) Control (N=287) Conjunctival hemorrhage 28% 17% 31% 21% Eye pain 9% 6% 11% 9% Cataract 8% 9% 19% 17% Vitreous floaters 6% 3% 8% 6% Corneal epithelium defect 5% 3% 7% 5% Intraocular pressure increased 5% 3% 9% 5% Ocular hyperemia 5% 6% 5% 6% Vitreous detachment 3% 3% 8% 6% Foreign body sensation in eyes 3% 3% 3% 3% Lacrimation increased 3% 2% 4% 2% Vision blurred 2% 2% 3% 4% Intraocular inflammation 2% <1% 3% 1% Injection site pain 2% <1% 2% <1% Eyelid edema <1% 1% 2% 1% Less common adverse reactions reported in <1% of the patients treated with aflibercept were hypersensitivity, retinal detachment, retinal tear, corneal edema, and injection site hemorrhage. Safety data observed in 269 patients with nonproliferative diabetic retinopathy (NPDR) through week 52 in the PANORAMA trial were consistent with those seen in the phase 3 VIVID and VISTA trials (see Table 3 above). 6.1 Postmarketing Experience The following adverse reactions have been identified during postapproval use of aflibercept. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Eye disorders: retinal vasculitis and occlusive retinal vasculitis related to intravitreal injection with aflibercept (reported at a rate of 0.6 and 0.2 per 1 million injections, respectively, based on postmarketing experience from November 2011 until November 2023). The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Formycon at 1-800-387-2746 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION."],"contraindications":["4. CONTRAINDICATIONS 4.1 Ocular or Periocular Infections AHZANTIVE is contraindicated in patients with ocular or periocular infections. 4.2 Active Intraocular Inflammation AHZANTIVE is contraindicated in patients with active intraocular inflammation. 4.3 Hypersensitivity AHZANTIVE is contraindicated in patients with known hypersensitivity to aflibercept or any of the excipients in AHZANTIVE. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions, or severe intraocular inflammation. Ocular or periocular infections (4.1) Active intraocular inflammation (4.2) Hypersensitivity (4.3)"],"how_supplied_table":["
NDC NumberCarton TypeCarton Contents
85006-8092-1Pre-filled Syringeone blister pack containing one AHZANTIVE 2 mg (0.05 mL of a 40 mg/mL solution) sterile, single‑dose pre-filled syringe one Prescribing Information
85006-2908-1Vial Onlyone AHZANTIVE 2 mg (0.05 mL of a 40 mg/mL solution) single-dose glass vial one Prescribing Information
"],"recent_major_changes":["Dosage and Administration (2.1, 2.6, 2.8) 4/2025"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept products act as soluble decoy receptors that bind VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors. 12.2 Pharmacodynamics Neovascular (Wet) Age-Related Macular Degeneration (AMD) In the clinical studies anatomic measures of disease activity improved similarly in all treatment groups from baseline to week 52. Anatomic data were not used to influence treatment decisions during the first year. Macular Edema Following Retinal Vein Occlusion (RVO) Reductions in mean retinal thickness were observed in COPERNICUS, GALILEO, and VIBRANT at week 24 compared to baseline. Anatomic data were not used to influence treatment decisions [see Clinical Studies (14.2), (14.3)]. Diabetic Macular Edema (DME) Reductions in mean retinal thickness were observed in VIVID and VISTA at weeks 52 and 100 compared to baseline. Anatomic data were not used to influence aflibercept treatment decisions [see Clinical Studies (14.4)]. 12.3 Pharmacokinetics Aflibercept is administered intravitreally to exert local effects in the eye. In patients with wet AMD, RVO, or DME, following intravitreal administration of aflibercept, a fraction of the administered dose is expected to bind with endogenous VEGF in the eye to form an inactive aflibercept: VEGF complex. Once absorbed into the systemic circulation, aflibercept presents in the plasma as free aflibercept (unbound to VEGF) and a more predominant stable inactive form with circulating endogenous VEGF (i.e., aflibercept: VEGF complex). Absorption/Distribution Following intravitreal administration of 2 mg per eye of aflibercept to patients with wet AMD, RVO, and DME, the mean Cmax of free aflibercept in the plasma was 0.02 mcg/mL (range: 0 to 0.054 mcg/mL), 0.05 mcg/mL (range: 0 to 0.081 mcg/mL), and 0.03 mcg/mL (range: 0 to 0.076 mcg/mL), respectively and was attained in 1 to 3 days. The free aflibercept plasma concentrations were undetectable two weeks post-dosing in all patients. Aflibercept did not accumulate in plasma when administered as repeated doses intravitreally every 4 weeks. It is estimated that after intravitreal administration of 2 mg to patients, the mean maximum plasma concentration of free aflibercept is more than 100 fold lower than the concentration of aflibercept required to half-maximally bind systemic VEGF. The volume of distribution of free aflibercept following intravenous (I.V.) administration of aflibercept has been determined to be approximately 6L. Metabolism/Elimination Aflibercept is a therapeutic protein and no drug metabolism studies have been conducted. Aflibercept is expected to undergo elimination through both target-mediated disposition via binding to free endogenous VEGF and metabolism via proteolysis. The terminal elimination half-life (t1/2) of free aflibercept in plasma was approximately 5 to 6 days after I.V. administration of doses of 2 to 4 mg/kg aflibercept. Specific Populations Renal Impairment Pharmacokinetic analysis of a subgroup of patients (n=492) in one wet AMD study, of which 43% had renal impairment (mild n=120, moderate n=74, and severe n=16), revealed no differences with respect to plasma concentrations of free aflibercept after intravitreal administration every 4 or 8 weeks. Similar results were seen in patients in a RVO study and in patients in a DME study. No dose adjustment based on renal impairment status is needed for either wet AMD, RVO, or DME patients. Other No dosage modification is required based on gender or in the elderly. 12.6 Immunogenicity The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of aflibercept or of other aflibercept products. In the wet AMD, RVO, and DME studies, the pre-treatment incidence of immunoreactivity to aflibercept was approximately 1% to 3% across treatment groups. After dosing with aflibercept for 24-100 weeks, antibodies to aflibercept were detected in a similar percentage range of patients. There were no differences in efficacy or safety between patients with or without immunoreactivity."],"indications_and_usage":["These highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. Approval: 2024 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) AHZANTIVE is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) (1.1) Macular Edema Following Retinal Vein Occlusion (RVO) (1.2) Diabetic Macular Edema (DME) (1.3) Diabetic Retinopathy (DR) (1.4)"],"warnings_and_cautions":["5. WARNINGS AND PRECAUTIONS 5.1 Endophthalmitis, Retinal Detachments, and Retinal Vasculitis with or without Occlusion Intravitreal injections, including those with aflibercept products, have been associated with endophthalmitis and retinal detachments [see Adverse Reactions (6.1)] and, more rarely, retinal vasculitis with or without occlusion [see Adverse Reactions (6.2)]. Proper aseptic injection technique must always be used when administering AHZANTIVE. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately [see Dosage and Administration (2.7) and Patient Counseling Information (17)]. 5.2 Increase in Intraocular Pressure Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with aflibercept products [see Adverse Reactions (6.1)]. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with vascular endothelial growth factor (VEGF) inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately [see Dosage and Administration (2.7)]. 5.3 Thromboembolic Events There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including aflibercept products. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with aflibercept compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the aflibercept group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with aflibercept compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with aflibercept compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with aflibercept in the first six months of the RVO studies. Endophthalmitis, retinal detachments, and retinal vasculitis with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment or retinal vasculitis without delay and should be managed appropriately. (5.1) Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. (5.2) There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. (5.3)"],"clinical_studies_table":["
VIEW 1VIEW 2
Aflibercept 2 mg Q8 weeks aAflibercept 2 mg Q4 weeks ranibizu-mab 0.5 mg Q4 weeks Aflibercept 2 mg Q8 weeks aAflibercept 2 mg Q4 weeks ranibizu-mab 0.5 mg Q4 weeks
N=301N=304N=304N=306N=309N=291
Efficacy Outcomes
Proportion of patients who maintained visual acuity (%) (<15 letters of BCVA loss) 94%95%94%95%95%95%
Differenceb (%) (95.1% CI)0.6 (-3.2, 4.4) 1.3 (-2.4, 5.0) 0.6 (-2.9, 4.0) -0.3 (-4.0, 3.3)
Mean change in BCVA as measured by ETDRS letter score from Baseline7.910.98.18.97.69.4
Difference b in LS mean (95.1% CI) 0.3 (-2.0, 2.5) 3.2 (0.9, 5.4) -0.9 (-3.1, 1.3) -2.0 (-4.1, 0.2)
Number of patients who gained at least 15 letters of vision from Baseline (%)92 (31%) 114 (38%) 94 (31%) 96 (31%) 91 (29%) 99 (34%)
Differenceb (%) (95.1% CI)-0.4 (-7.7, 7.0) 6.6 (-1.0, 14.1) -2.6 (-10.2, 4.9) -4.6 (-12.1, 2.9)
","
COPERNICUSGALILEO
ControlAflibercept 2 mg Q4 weeks ControlAflibercept 2 mg Q4 weeks
N=73N=114N=68N=103
Efficacy Outcomes
Proportion of patients who gained at least 15 letters in BCVA from Baseline (%)12%56%22%60%
Weighted Difference a, b (%) (95.1% CI) 44.8% c (32.9, 56.6) 38.3% c (24.4, 52.1)
Mean change in BCVA as measured by ETDRS letter score from Baseline (SD)-4.0 (18.0) 17.3 (12.8) 3.3 (14.1) 18.0 (12.2)
Difference in LS mean a, d (95.1% CI) 21.7c (17.3, 26.1) 14.7 c (10.7, 18.7)
","
VIBRANT
ControlAflibercept 2 mg Q4 weeks
N=90N=91
Efficacy Outcomes
Proportion of patients who gained at least 15 letters in BCVA from Baseline (%)26.7%52.7%
Weighted Difference a, b (%) (95% CI) 26.6% c (13.0, 40.1)
Mean change in BCVA as measured by ETDRS letter score from Baseline (SD)6.9 (12.9) 17.0 (11.9)
Difference in LS mean a, d (95% CI) 10.5 c (7.1, 14.0)
","
VIVIDVISTA
Aflibercept 2 mg Q8 weeks aAflibercept 2 mg Q4 weeks ControlAflibercept 2 mg Q8 weeks aAflibercept 2 mg Q4 weeks Control
Full Analysis SetN=135N=136N=132N=151N=154N=154
Efficacy Outcomes at Week 52
Mean change in BCVA as measured by ETDRS letter score from Baseline (SD)10.7 (9.3) 10.5 (9.6) 1.2 (10.6) 10.7 (8.2) 12.5 (9.5) 0.2 (12.5)
Difference b, c in LS mean (97.5% CI) 9.1 d (6.3, 11.8) 9.3 d (6.5, 12.0) 10.5 d (7.7, 13.2) 12.2 d (9.4, 15.0)
Proportion of patients who gained at least 15 letters in BCVA from Baseline (%) 33.3%32.4%9.1%31.1%41.6%7.8%
Adjusted Difference c, e (%) (97.5% CI) 24.2 d (13.5, 34.9) 23.3 d (12.6, 33.9) 23.3 d (13.5, 33.1) 34.2 d (24.1, 44.4)
Efficacy Outcomes at Week 100
Mean change in BCVA as measured by ETDRS letter score from Baseline (SD)9.4 (10.5) 11.4 (11.2) 0.7 (11.8) 11.1 (10.7) 11.5 (13.8) 0.9 (13.9)
Differenceb, c in LS mean (97.5% CI) 8.2d (5.2, 11.3) 10.7 d (7.6, 13.8) 10.1 d (7.0, 13.3) 10.6 d (7.1, 14.2)
Proportion of patients who gained at least 15 letters in BCVA from Baseline (%) 31.1%38.2%12.1%33.1%38.3%13.0%
Adjusted Difference c, e (%) (97.5% CI) 19.0 d (8.0, 29.9) 26.1 d (14.8, 37.5) 20.1 d (9.6, 30.6) 25.8 d (15.1, 36.6)
","
VIVIDVISTA
Aflibercept 2 mg Q8 weeks aAflibercept 2 mg Q4 weeks ControlAflibercept 2 mg Q8 weeks aAflibercept 2 mg Q4 weeks Control
Evaluable Patients bN=101N=97N=99N=148N=153N=150
Number of patients with a ≥2-step improvement on ETDRS-DRSS from Baseline (%)32 (32%) 27 (28%) 7 (7%) 56 (38%) 58 (38%) 24 (16%)
Difference c,d (%) (97.5% CI) 24% e (12, 36) 21% e (9, 33) 22% e (11, 33) 22% e (11, 33)
","
PANORAMA
Week 24Week 52
Aflibercept CombinedControl (sham) Aflibercept 2Q16Aflibercept 2Q8 Control (sham)
Full Analysis SetN=269N=133N=135N=134N=133
Proportion of patients with a ≥2-step improvement on ETDRS-DRSS from Baseline (%)58%6%65%80%15%
Adjusted Difference a (%) (95% CI) b52% c (45, 60) 50% c (40, 60) 65% c (56, 74)
","
Aflibercept 2Q16 Aflibercept 2Q8 Control (sham)
Full Analysis SetN=135N=134N=133
Composite Endpoint of Developing PDR or ASNV a
Event Rate b4.0% d2.4% d20.1%
Hazard Ratio0.150.12
Development of Proliferative Diabetic Retinopathy c
Event Rate b1.6% d0.0% d11.9%
Hazard Ratio0.110.00
"],"nonclinical_toxicology":["12 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been conducted on the mutagenic or carcinogenic potential of afliberceptproducts . Effects on male and female fertility were assessed as part of a 6-month study in monkeys with intravenous administration of aflibercept at weekly doses ranging from 3 to 30 mg per kg. Absent or irregular menses associated with alterations in female reproductive hormone levels and changes in sperm morphology and motility were observed at all dose levels. In addition, females showed decreased ovarian and uterine weight accompanied by compromised luteal development and reduction of maturing follicles. These changes correlated with uterine and vaginal atrophy. A No Observed Adverse Effect Level (NOAEL) was not identified. Intravenous administration of the lowest dose of aflibercept assessed in monkeys (3 mg per kg) resulted in systemic exposure (AUC) for free aflibercept that was approximately 1500 times higher than the systemic exposure observed in adult patients after an intravitreal dose of 2 mg. All changes were reversible within 20 weeks after cessation of treatment. 13.2 Animal Toxicology and/or Pharmacology Erosions and ulcerations of the respiratory epithelium in nasal turbinates in monkeys treated with aflibercept intravitreally were observed at intravitreal doses of 2 or 4 mg per eye. At the NOAEL of 0.5 mg per eye in monkeys, the systemic exposure (AUC) was 56 times higher than the exposure observed in adult patients after an intravitreal dose of 2 mg. Similar effects were not seen in other clinical studies [see Clinical Studies (14)]."],"adverse_reactions_table":["
Adverse ReactionsBaseline to Week 52Baseline to Week 96
Aflibercept (N=1824) Active Control (ranibizumab) (N=595) Aflibercept (N=1824) Control (ranibizumab) (N=595)
Conjunctival hemorrhage25%28%27%30%
Eye pain9%9%10%10%
Cataract7%7%13%10%
Vitreous detachment6%6%8%8%
Vitreous floaters6%7%8%10%
Intraocular pressure increased5%7%7%11%
Ocular hyperemia4%8%5%10%
Corneal epithelium defect4%5%5%6%
Detachment of the retinal pigment epithelium3%3%5%5%
Injection site pain3%3%3%4%
Foreign body sensation in eyes3%4%4%4%
Lacrimation increased3%1%4%2%
Vision blurred2%2%4%3%
Intraocular inflammation2%3%3%4%
Retinal pigment epithelium tear2%1%2%2%
Injection site hemorrhage1%2%2%2%
Eyelid edema1%2%2%3%
Corneal edema1%1%1%1%
Retinal detachment<1%<1%1%1%
","
Adverse ReactionsCRVOBRVO
Aflibercept (N=218) Control (N=142) Aflibercept (N=91) Control (N=92)
Eye pain13%5%4%5%
Conjunctival hemorrhage12%11%20%4%
Intraocular pressure increased8%6%2%0%
Corneal epithelium defect5%4%2%0%
Vitreous floaters5%1%1%0%
Ocular hyperemia5%3%2%2%
Foreign body sensation in eyes3%5%3%0%
Vitreous detachment3%4%2%0%
Lacrimation increased3%4%3%0%
Injection site pain3%1%1%0%
Vision blurred1%<1%1%1%
Intraocular inflammation1%1%0%0%
Cataract<1%1%5%0%
Eyelid edema<1%1%1%0%
","
Adverse ReactionsBaseline to Week 52Baseline to Week 100
Aflibercept (N=578) Control (N=287) Aflibercept (N=578) Control (N=287)
Conjunctival hemorrhage28%17%31%21%
Eye pain9%6%11%9%
Cataract8%9%19%17%
Vitreous floaters6%3%8%6%
Corneal epithelium defect5%3%7%5%
Intraocular pressure increased5%3%9%5%
Ocular hyperemia5%6%5%6%
Vitreous detachment3%3%8%6%
Foreign body sensation in eyes3%3%3%3%
Lacrimation increased3%2%4%2%
Vision blurred2%2%3%4%
Intraocular inflammation2%<1%3%1%
Injection site pain2%<1%2%<1%
Eyelid edema<1%1%2%1%
"],"spl_unclassified_section":["17 PATIENT COUNSELING INFORMATION In the days following AHZANTIVE administration, patients are at risk of developing endophthalmitis, retinal detachment, or retinal vasculitis with or without occlusion. If the eye becomes red, sensitive to light, painful, or develops a change in vision, advise patients and/or caregivers to seek immediate care from an ophthalmologist [see Warnings and Precautions (5.1)]. Patients may experience temporary visual disturbances after an intravitreal injection with AHZANTIVE and the associated eye examinations [see Adverse Reactions (6)]. Advise patients not to drive or use machinery until visual function has recovered sufficiently."],"dosage_and_administration":["2. DOSAGE AND ADMINISTRATION 2.1 Important Injection Instructions For ophthalmic intravitreal injection. AHZANTIVE must only be administered by a qualified physician. Pre-filled Syringe: A 30-gauge × ½-inch sterile injection needle is needed but not provided. Vial: A 5-micron sterile filter needle (18-gauge × 1½-inch), a 1-mL sterile Luer lock syringe and a 30‑gauge × ½-inch sterile injection needle are needed, but not provided. AHZANTIVE is available packaged as follows: Pre-filled Syringe. The AHZANTIVE pre-filled syringe cap and plunger are not made with natural rubber latex. Vial Only. The AHZANTIVE vial stopper is not made with natural rubber latex. [see How Supplied/Storage and Handling (16)]. 2.2 Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for AHZANTIVE is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months). Although AHZANTIVE may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when aflibercept was dosed every 4 weeks compared to every 8 weeks [see Clinical Studies (14.1)] . Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months). Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly. 2.3 Macular Edema Following Retinal Vein Occlusion (RVO) The recommended dose for AHZANTIVE is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection once every 4 weeks (approximately every 25 days, monthly) [see Clinical Studies (14.2), (14.3)]. 2.4 Diabetic Macular Edema (DME) The recommended dose for AHZANTIVE is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections, followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months). Although AHZANTIVE may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when aflibercept was dosed every 4 weeks compared to every 8 weeks [see Clinical Studies (14.4)] . Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months). 2.5 Diabetic Retinopathy (DR) The recommended dose for AHZANTIVE is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections, followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months). Although AHZANTIVE may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when aflibercept was dosed every 4 weeks compared to every 8 weeks [see Clinical Studies (14.5)] . Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months). 2.6 Preparation for Administration - Pre-filled Syringe The AHZANTIVE pre-filled syringe is sterile and for one-time use in one eye only. The pre-filled syringe should be inspected visually prior to administration. Do not use if particulates, cloudiness, or discoloration are visible, or if the package is open or damaged. Do not use if any part of the pre-filled syringe is damaged or if the syringe cap is detached from the Luer lock. The intravitreal injection should be performed with a 30-gauge x ½-inch injection needle (not provided). The pre-filled syringe contains more than the recommended dose of 2 mg aflibercept-mrbb (equivalent to 50 microliters). The excess volume must be discarded prior to the administration. PRE-FILLED SYRINGE DESCRIPTION - Figure 1: Use aseptic technique to carry out the following steps: 1. PREPARE When ready to administer AHZANTIVE, open the carton and remove sterilized blister pack. Carefully peel open the sterilized blister pack ensuring the sterility of its contents. Keep the syringe in the sterile tray until you are ready for assembly. 2. REMOVE SYRINGE Using aseptic technique, remove the syringe from the sterilized blister pack. 3. TWIST OFF SYRINGE CAP Twist off (do not snap off) the syringe cap by holding the syringe in one hand and the syringe cap with the thumb and forefinger of the other hand (see Figure 2). Figure 2: 4. ATTACH NEEDLE Using aseptic technique, firmly twist a 30-gauge x ½-inch injection needle onto the Luer lock syringe tip (see Figure 3). Figure 3: Note: When ready to administer AHZANTIVE, remove the plastic needle shield from the needle. 5. DISLODGE AIR BUBBLES Holding the syringe with the needle pointing up, check the syringe for bubbles. If there are bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see Figure 4). Figure 4: 6. EXPEL AIR AND SET THE DOSE To eliminate all bubbles and to expel excess drug, slowly depress the plunger rod to align the plunger dome edge (see Figure 5a) with the black dosing line on the syringe (equivalent to 50 microliters) (see Figure 5b). Figure 5a: Figure 5b: 7. The pre-filled syringe is for one-time use in one eye only. After injection any unused product must be discarded. 2.7 Preparation for Administration - Vial AHZANTIVE should be inspected visually prior to administration. If particulates, cloudiness, or discoloration are visible, the vial must not be used. The glass vial is for one-time use in one eye only. Discard unused portion. Use aseptic technique to carry out the following preparation steps: Prepare for intravitreal injection with the following medical devices for single use (not provided): a 5-micron sterile filter needle (18-gauge × 1½-inch) a 1-mL sterile Luer lock syringe (with marking to measure 0.05 mL) a sterile injection needle (30-gauge × ½-inch) 1. Remove the protective plastic cap from the vial (see Figure 6). Figure 6: 2. Clean the top of the vial with an alcohol wipe (see Figure 7). Figure 7: 3. Remove the 18-gauge x 1½-inch, 5-micron, filter needle and the 1-mL syringe from their packaging. Attach the filter needle to the syringe by twisting it onto the Luer lock syringe tip (see Figure 8). Figure 8: 4. Push the filter needle into the center of the vial stopper until the needle is completely inserted into the vial and the tip touches the bottom or bottom edge of the vial. 5. Using aseptic technique withdraw all of the AHZANTIVE vial contents into the syringe, keeping the vial in an upright position, slightly inclined to ease complete withdrawal. To deter the introduction of air, ensure the bevel of the filter needle is submerged into the liquid. Continue to tilt the vial during withdrawal keeping the bevel of the filter needle submerged in the liquid (see Figure 9a and Figure 9b). Figure 9a: Figure 9b: 6. Ensure that the plunger rod is drawn sufficiently back when emptying the vial in order to completely empty the filter needle. 7. Remove the filter needle from the syringe and properly dispose of the filter needle. Note: Filter needle is not to be used for intravitreal injection. 8. Remove the 30-gauge x ½-inch injection needle from its packaging and attach the injection needle to the syringe by firmly twisting the injection needle onto the Luer lock syringe tip (see Figure 10). Figure 10: 9. When ready to administer AHZANTIVE, remove the plastic needle shield from the needle. 10. Holding the syringe with the needle pointing up, check the syringe for bubbles. If there are bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see Figure 11). Figure 11: 11. To eliminate all of the bubbles and to expel excess drug, SLOWLY depress the plunger rod so that the plunger edge aligns with the line that marks 0.05 mL on the syringe (see Figure 12a and Figure 12b). Figure 12a: Figure 12b: 2.8 Injection Procedure The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include surgical hand disinfection and the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a topical broad–spectrum microbicide should be given prior to the injection. Pre-filled syringe: Inject by pressing the plunger carefully and with constant pressure. Do not apply additional pressure once the plunger has reached the bottom of the syringe. A small residual volume may remain in the syringe after a full dose has been injected. This is normal. Do not administer any residual solution observed in the syringe. Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available. Following intravitreal injection, patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis or retinal detachment (e.g., eye pain, redness of the eye, photophobia, blurring of vision) without delay [see Patient Counseling Information (17)]. Each sterile vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new sterile vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before AHZANTIVE is administered to the other eye. After injection, any unused product must be discarded. Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for AHZANTIVE is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months). (2 . 2) Although AHZANTIVE may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when aflibercept was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months). (2 . 2) Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly. (2.2) Macular Edema Following Retinal Vein Occlusion (RVO) The recommended dose for AHZANTIVE is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection once every 4 weeks (approximately every 25 days, monthly). (2.3) Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) The recommended dose for AHZANTIVE is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months). (2.4, 2.5) Although AHZANTIVE may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when aflibercept was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months). (2.4, 2.5) Figure 1 figure 2 figure 3 figure 4 figure 5a figure 5b figure 6 figure 7 figure 8 figure 9a figure 9b figure 10 figure 11 figure 12a figure 12b"],"spl_product_data_elements":["AHZANTIVE aflibercept-mrbb AFLIBERCEPT-MRBB AFLIBERCEPT-MRBB"],"dosage_forms_and_strengths":["3. DOSAGE FORMS AND STRENGTHS AHZANTIVE is a clear, colorless to pale yellow solution available as: Injection: 2 mg (0.05 mL of a 40 mg/mL solution) in a single-dose pre-filled syringe Injection: 2 mg (0.05 mL of a 40 mg/mL solution) in a single-dose glass vial Injection: 2 mg (0.05 mL of 40 mg/mL) solution in a single-dose pre-filled syringe (3) Injection: 2 mg (0.05 mL of 40 mg/mL) solution in a single-dose vial (3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Adequate and well-controlled studies with aflibercept have not been conducted in pregnant women. Aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations. A fetal No Observed Adverse Effect Level (NOAEL) was not identified. At the lowest dose shown to produce adverse embryofetal effects, systemic exposures (based on AUC for free aflibercept) were approximately 6 times higher than AUC values observed in humans after a single intravitreal treatment at the recommended clinical dose [see Animal Data]. Animal reproduction studies are not always predictive of human response, and it is not known whether aflibercept can cause fetal harm when administered to a pregnant woman. Based on the anti-VEGF mechanism of action for aflibercept [see Clinical Pharmacology (12.1)], treatment with aflibercept may pose a risk to human embryofetal development. AHZANTIVE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In two embryofetal development studies, aflibercept produced adverse embryofetal effects when administered every three days during organogenesis to pregnant rabbits at intravenous doses ≥3 mg per kg, or every six days during organogenesis at subcutaneous doses ≥0.1 mg per kg. Adverse embryofetal effects included increased incidences of postimplantation loss and fetal malformations, including anasarca, umbilical hernia, diaphragmatic hernia, gastroschisis, cleft palate, ectrodactyly, intestinal atresia, spina bifida, encephalomeningocele, heart and major vessel defects, and skeletal malformations (fused vertebrae, sternebrae, and ribs; supernumerary vertebral arches and ribs; and incomplete ossification). The maternal No Observed Adverse Effect Level (NOAEL) in these studies was 3 mg per kg. Aflibercept produced fetal malformations at all doses assessed in rabbits and the fetal NOAEL was not identified. At the lowest dose shown to produce adverse embryofetal effects in rabbits (0.1 mg per kg), systemic exposure (AUC) of free aflibercept was approximately 6 times higher than systemic exposure (AUC) observed in adult patients after a single intravitreal dose of 2 mg. 8.2 Lactation Risk Summary There is no information regarding the presence of aflibercept products in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production/excretion. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, AHZANTIVE is not recommended during breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AHZANTIVE and any potential adverse effects on the breastfed child from AHZANTIVE. 8.3 Females and Males of Reproductive Potential Contraception Females of reproductive potential are advised to use effective contraception prior to the initial dose, during treatment, and for at least 3 months after the last intravitreal injection of AHZANTIVE. Infertility There are no data regarding the effects of aflibercept on human fertility. Aflibercept adversely affected female and male reproductive systems in cynomolgus monkeys when administered by intravenous injection at a dose approximately 1500 times higher than the systemic level observed in adult patients with an intravitreal dose of 2 mg. A No Observed Adverse Effect Level (NOAEL) was not identified. These findings were reversible within 20 weeks after cessation of treatment [see Nonclinical Toxicology (13.1)]. 8.4 Pediatric Use A pediatric assessment for AHZANTIVE demonstrates that AHZANTIVE is safe and effective for pediatric patients in an indication for which EYLEA (aflibercept) is approved. However, AHZANTIVE is not approved for such indication due to marketing exclusivity for EYLEA (aflibercept). 8.5 Geriatric Use In the clinical studies, approximately 76% (2049/2701) of patients randomized to treatment with aflibercept were ≥65 years of age and approximately 46% (1250/2701) were ≥75 years of age. No significant differences in efficacy or safety were seen with increasing age in these studies."],"package_label_principal_display_panel":["PPP p"]},"tags":[{"label":"Vascular Endothelial Growth Factor Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Vascular endothelial growth factor A","category":"target"},{"label":"VEGFA","category":"gene"},{"label":"VEGFB","category":"gene"},{"label":"PGF","category":"gene"},{"label":"L01XX44","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Intravitreal","category":"route"},{"label":"Injection","category":"form"},{"label":"Solution","category":"form"},{"label":"Active","category":"status"},{"label":"Branch retinal vein occlusion with macular edema","category":"indication"},{"label":"Central retinal vein occlusion with macular edema","category":"indication"},{"label":"Exudative age-related macular degeneration","category":"indication"},{"label":"Macular edema due to diabetes mellitus","category":"indication"},{"label":"Metastasis from malignant tumor of colon","category":"indication"},{"label":"Neovascular glaucoma","category":"indication"},{"label":"Regeneron Pharmaceuticals","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Angiogenesis Inhibitors","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Growth Inhibitors","category":"pharmacology"},{"label":"Growth Substances","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"7914 reports"},{"date":"","signal":"VISUAL IMPAIRMENT","source":"FDA FAERS","actionTaken":"2019 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1529 reports"},{"date":"","signal":"BLINDNESS","source":"FDA FAERS","actionTaken":"1461 reports"},{"date":"","signal":"ENDOPHTHALMITIS","source":"FDA FAERS","actionTaken":"1378 reports"},{"date":"","signal":"VISUAL ACUITY REDUCED","source":"FDA FAERS","actionTaken":"1245 reports"},{"date":"","signal":"EYE PAIN","source":"FDA FAERS","actionTaken":"1191 reports"},{"date":"","signal":"VISION BLURRED","source":"FDA FAERS","actionTaken":"1164 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1140 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"1078 reports"}],"commonSideEffects":[{"effect":"Leukopenia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Neutropenia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Proteinuria","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"AST increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Stomatitis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Fatigue","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Thrombocytopenia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"ALT increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hypertension","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Weight decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Decreased appetite","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Epistaxis","drugRate":"28%","severity":"common","_validated":true},{"effect":"Abdominal pain","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dysphonia","drugRate":"25%","severity":"common","_validated":true},{"effect":"Serum creatinine increased","drugRate":"23%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Asthenia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dehydration","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Infections","drugRate":"reported","severity":"serious"},{"effect":"Venous thromboembolic events","drugRate":"reported","severity":"serious"},{"effect":"Severe hypersensitivity reactions","drugRate":"reported","severity":"serious"},{"effect":"Pulmonary embolism","drugRate":"reported","severity":"serious"},{"effect":"Urinary tract infection","drugRate":"reported","severity":"mild"},{"effect":"Nasopharyngitis","drugRate":"reported","severity":"mild"},{"effect":"Upper respiratory tract infection","drugRate":"reported","severity":"mild"},{"effect":"Tooth infection","drugRate":"reported","severity":"mild"}],"specialPopulations":{"Pregnancy":"Adequate and well-controlled studies with EYLEA have not been conducted in pregnant women. Aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations. fetal No Observed Adverse Effect Level (NOAEL) was not identified. At the lowest dose shown to produce adverse embryofetal effects, systemic exposures (based on AUC for free aflibercept) were approximately times higher than AUC values observed in humans after single intravitreal treatment at the recommended clinical dose. EYLEA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.","Geriatric use":"In the clinical studies, approximately 76% (2049/2701) of patients randomized to treatment with EYLEA were >=65 years of age and approximately 46% (1250/2701) were >=75 years of age. No significant differences in efficacy or safety were seen with increasing age in these studies.","Paediatric use":"The safety and effectiveness of EYLEA in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Regeneron","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AFLIBERCEPT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:39:06.693262+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:39:13.462971+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:39:06.764744+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:39:05.811729+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AFLIBERCEPT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:39:13.675962+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:02.606843+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:02.606871+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:39:15.216831+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Placenta growth factor inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:39:14.798878+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1742982/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:39:14.464316+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761378","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:02.606875+00:00"}},"allNames":"eylea, vegf trap, vegf-trap, zaltrap","offLabel":[],"synonyms":["aflibercept","eylea","AVE0005","ziv-aflibercept","zaltrap","VEGF Trap"],"timeline":[{"date":"2011-11-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Regeneron Pharmaceuticals)"},{"date":"2012-11-22","type":"positive","source":"DrugCentral","milestone":"EMA approval"},{"date":"2020-03-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Bayer Yakuhin, Ltd)"}],"aiSummary":"Aflibercept, also known as Vegf Trap, is a vascular endothelial growth factor inhibitor developed by Regeneron Pharmaceuticals. It works by binding to vascular endothelial growth factor A, preventing its interaction with its receptor and thereby inhibiting angiogenesis. Aflibercept is approved to treat various eye conditions, including macular edema and age-related macular degeneration, as well as metastatic colorectal cancer. It is a small molecule drug that has been commercially available since 2011. Key safety considerations include potential increased risk of hypertension, proteinuria, and gastrointestinal perforation.","brandName":"Vegf Trap","ecosystem":[{"indication":"Branch retinal vein occlusion with macular edema","otherDrugs":[{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"ranibizumab","slug":"ranibizumab","company":"Genentech"}],"globalPrevalence":null},{"indication":"Central retinal vein occlusion with macular edema","otherDrugs":[{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"ranibizumab","slug":"ranibizumab","company":"Genentech"}],"globalPrevalence":2240000},{"indication":"Exudative age-related macular degeneration","otherDrugs":[{"name":"brolucizumab","slug":"brolucizumab","company":"Novartis Pharms Corp"},{"name":"faricimab","slug":"faricimab","company":"Genentech Inc"},{"name":"pegaptanib","slug":"pegaptanib","company":"Valeant Pharms Llc"},{"name":"ranibizumab","slug":"ranibizumab","company":"Genentech"}],"globalPrevalence":900000000},{"indication":"Macular edema due to diabetes mellitus","otherDrugs":[{"name":"brolucizumab","slug":"brolucizumab","company":"Novartis Pharms Corp"},{"name":"faricimab","slug":"faricimab","company":"Genentech Inc"},{"name":"ranibizumab","slug":"ranibizumab","company":"Genentech"}],"globalPrevalence":null},{"indication":"Metastasis from malignant tumor of colon","otherDrugs":[{"name":"capecitabine","slug":"capecitabine","company":"Hoffmann La Roche"},{"name":"fluorouracil","slug":"fluorouracil","company":"Spectrum Pharms"},{"name":"irinotecan","slug":"irinotecan","company":"Pfizer Inc"},{"name":"oxaliplatin","slug":"oxaliplatin","company":""}],"globalPrevalence":null},{"indication":"Neovascular glaucoma","otherDrugs":[],"globalPrevalence":1952000},{"indication":"Retinopathy of prematurity","otherDrugs":[{"name":"ranibizumab","slug":"ranibizumab","company":"Genentech"}],"globalPrevalence":null}],"mechanism":{"target":"Vascular endothelial growth factor A","novelty":"Follow-on","targets":[{"gene":"VEGFA","source":"DrugCentral","target":"Vascular endothelial growth factor A","protein":"Vascular endothelial growth factor A"},{"gene":"VEGFB","source":"DrugCentral","target":"Vascular endothelial growth factor B","protein":"Vascular endothelial growth factor B"},{"gene":"PGF","source":"DrugCentral","target":"Placenta growth factor","protein":"Placenta growth factor"}],"moaClass":"Vascular Endothelial Growth Factor Inhibitors","modality":"Small Molecule","drugClass":"Vascular Endothelial Growth Factor Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Aflibercept is a recombinant fusion protein that consists of the extracellular domains of human vascular endothelial growth factor receptors 1 and 2, linked to the Fc region of human immunoglobulin G1. It binds to vascular endothelial growth factor A with high affinity, preventing its interaction with its receptor and thereby inhibiting angiogenesis."},"commercial":{"launchDate":"2011","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2011-11-18, REGENERON PHARMACEUTICALS)","annualRevenue":9800,"revenueSource":"Verified: Bayer/Regeneron AR","revenueCurrency":"USD","revenueConfidence":"verified","revenueExtractedAt":"2026-04-01T11:47:26.185712","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4916","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AFLIBERCEPT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AFLIBERCEPT","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:30:12.164076","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:39:17.333437+00:00","fieldsConflicting":17,"overallConfidence":0.8},"biosimilars":[{"form":"SOLUTION, CONCENTRATE","route":"INTRAVENOUS","company":"sanofi-aventis U.S. LLC","brandName":"ZALTRAP","isOriginal":false,"marketingStatus":"BLA"}],"competitors":[{"drugName":"asparaginase","drugSlug":"asparaginase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"altretamine","drugSlug":"altretamine","fdaApproval":"1990-12-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hydroxycarbamide","drugSlug":"hydroxycarbamide","fdaApproval":"1967-12-07","relationship":"same-class"},{"drugName":"pentostatin","drugSlug":"pentostatin","fdaApproval":"1991-10-11","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"masoprocol","drugSlug":"masoprocol","fdaApproval":"1992-09-04","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mitotane","drugSlug":"mitotane","fdaApproval":"1970-07-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"pegaspargase","drugSlug":"pegaspargase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"arsenic trioxide","drugSlug":"arsenic-trioxide","fdaApproval":"2000-09-25","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"denileukin diftitox","drugSlug":"denileukin-diftitox","fdaApproval":"1999-02-05","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"anagrelide","drugSlug":"anagrelide","fdaApproval":"1997-03-14","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"omacetaxine mepesuccinate","drugSlug":"omacetaxine-mepesuccinate","fdaApproval":"2012-10-26","patentExpiry":"Oct 26, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eribulin","drugSlug":"eribulin","fdaApproval":"2010-11-15","patentExpiry":"Jul 8, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"venetoclax","drugSlug":"venetoclax","fdaApproval":"2016-04-11","patentExpiry":"Sep 6, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"enasidenib","drugSlug":"enasidenib","fdaApproval":"2017-08-01","patentExpiry":"Sep 16, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivosidenib","drugSlug":"ivosidenib","fdaApproval":"2018-07-20","patentExpiry":"Oct 18, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selinexor","drugSlug":"selinexor","fdaApproval":"2019-07-03","patentExpiry":"Jul 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tagraxofusp","drugSlug":"tagraxofusp","fdaApproval":"2018-12-21","relationship":"same-class"},{"drugName":"lurbinectedin","drugSlug":"lurbinectedin","fdaApproval":"2020-06-15","patentExpiry":"May 29, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tazemetostat","drugSlug":"tazemetostat","fdaApproval":"2020-01-23","patentExpiry":"Sep 12, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"aflibercept","indications":{"approved":[{"name":"Branch retinal vein occlusion with macular edema","source":"DrugCentral","snomedId":232048009,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Central retinal vein occlusion with macular edema","source":"DrugCentral","snomedId":232039004,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","usPrevalence":null,"globalPrevalence":2240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medecines Agency 2014[INST])"},{"name":"Exudative age-related macular degeneration","source":"DrugCentral","snomedId":414173003,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","usPrevalence":null,"globalPrevalence":900000000,"prevalenceMethod":"curated","prevalenceSource":"Retina, 2018 (PMID:29059101)"},{"name":"Macular edema due to diabetes mellitus","source":"DrugCentral","snomedId":312912001,"regulator":"FDA"},{"name":"Metastasis from malignant tumor of colon","source":"DrugCentral","snomedId":314998002,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Neovascular glaucoma","source":"DrugCentral","snomedId":232086000,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","prevalenceClass":"1-5 / 10 000","globalPrevalence":1952000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2003[INST])"},{"name":"Retinopathy of prematurity","source":"DrugCentral","snomedId":415297005,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"asparaginase","brandName":"asparaginase","genericName":"asparaginase","approvalYear":"1994","relationship":"same-class"},{"drugId":"altretamine","brandName":"altretamine","genericName":"altretamine","approvalYear":"1990","relationship":"same-class"},{"drugId":"hydroxycarbamide","brandName":"hydroxycarbamide","genericName":"hydroxycarbamide","approvalYear":"1967","relationship":"same-class"},{"drugId":"pentostatin","brandName":"pentostatin","genericName":"pentostatin","approvalYear":"1991","relationship":"same-class"},{"drugId":"masoprocol","brandName":"masoprocol","genericName":"masoprocol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mitotane","brandName":"mitotane","genericName":"mitotane","approvalYear":"1970","relationship":"same-class"},{"drugId":"pegaspargase","brandName":"pegaspargase","genericName":"pegaspargase","approvalYear":"1994","relationship":"same-class"},{"drugId":"arsenic-trioxide","brandName":"arsenic trioxide","genericName":"arsenic trioxide","approvalYear":"2000","relationship":"same-class"},{"drugId":"denileukin-diftitox","brandName":"denileukin diftitox","genericName":"denileukin diftitox","approvalYear":"1999","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02298959","phase":"PHASE1","title":"Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-04-08","conditions":["Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Colorectal Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Ovarian Carcinoma","Metastatic Renal Cell Carcinoma","Platinum-Resistant Ovarian Carcinoma","Recurrent Melanoma","Recurrent Renal Cell Carcinoma","Refractory Melanoma","Refractory Renal Cell Carcinoma","Sarcoma","Stage IV Colorectal Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":59,"completionDate":"2027-01-20"},{"nctId":"NCT07496567","phase":"PHASE2,PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-04-30","conditions":["Macular Degeneration","Age-Related Macular Degeneration","Choroidal Neovascularization","Wet Macular Degeneration"],"enrollment":960,"completionDate":"2028-07-31"},{"nctId":"NCT04515524","phase":"","title":"Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-02-05","conditions":["Retinopathy of Prematurity"],"enrollment":100,"completionDate":"2026-11-05"},{"nctId":"NCT06864988","phase":"PHASE3","title":"4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-03-03","conditions":["Macular Neovascularization Secondary to Age-Related Macular Degeneration"],"enrollment":480,"completionDate":"2028-06"},{"nctId":"NCT07489586","phase":"PHASE3","title":"A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":["Neovascular Age-Related Macular Degeneration (nAMD)"],"enrollment":356,"completionDate":"2027-08"},{"nctId":"NCT07489131","phase":"PHASE3","title":"Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"Alvotech Swiss AG","startDate":"2026-03","conditions":["Diabetic Macular Edema"],"enrollment":256,"completionDate":"2028-01"},{"nctId":"NCT07482176","phase":"PHASE3","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)","status":"RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2026-03-16","conditions":["Neovascular Age-Related Macular Degeneration (nAMD)","Wet AMD"],"enrollment":284,"completionDate":"2031-10-20"},{"nctId":"NCT06315556","phase":"","title":"An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-03-05","conditions":["Retinopathy of Prematurity","Preterm Infants"],"enrollment":200,"completionDate":"2027-04-30"},{"nctId":"NCT07118670","phase":"PHASE4","title":"High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Wood, MD","startDate":"2025-12-08","conditions":["Proliferative Diabetic Retinopathy (PDR)"],"enrollment":40,"completionDate":"2028-04"},{"nctId":"NCT06893965","phase":"NA","title":"Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2025-07-08","conditions":["Macular Diseases"],"enrollment":100,"completionDate":"2027-07"},{"nctId":"NCT07481500","phase":"NA","title":"Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","status":"NOT_YET_RECRUITING","sponsor":"Jakkrit Juhong","startDate":"2026-06","conditions":["Neovascular Age-Related Macular Degeneration (nAMD)","Diabetic Macular Edema","Retinal Vein Occlusion","Intravitreal Injections"],"enrollment":120,"completionDate":"2027-08"},{"nctId":"NCT07449936","phase":"PHASE3","title":"COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-26","conditions":["Diabetic Macular Edema","DME","Diabetic Macular Edema (DME)"],"enrollment":240,"completionDate":"2028-08"},{"nctId":"NCT07362927","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":["Diabetic Macular Edema (DME)"],"enrollment":32,"completionDate":"2031-09"},{"nctId":"NCT06929143","phase":"","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-04-14","conditions":["Neovascular Age-related Macular Degeneration (nAMD)","Diabetic Macular Edema (DME)"],"enrollment":3000,"completionDate":"2027-07-30"},{"nctId":"NCT06196840","phase":"PHASE2","title":"Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innostellar Biotherapeutics Co.,Ltd","startDate":"2024-01-24","conditions":["Neovascular Age-Related Macular Degeneration"],"enrollment":50,"completionDate":"2029-10"},{"nctId":"NCT07317934","phase":"PHASE3","title":"Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)","status":"RECRUITING","sponsor":"Innostellar Biotherapeutics Co.,Ltd","startDate":"2026-01-14","conditions":["Neovascular Age-Related Macular Degeneration (nAMD)","Wet AMD"],"enrollment":332,"completionDate":"2032-06-04"},{"nctId":"NCT07449923","phase":"PHASE3","title":"CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-09","conditions":["Diabetic Macular Edema","DME","Diabetic Macular Edema (DME)"],"enrollment":240,"completionDate":"2028-08"},{"nctId":"NCT06668064","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-10-22","conditions":["Wet Age Related Macular Degeneration","wAMD"],"enrollment":400,"completionDate":"2027-08"},{"nctId":"NCT06683742","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-11-27","conditions":["Wet Age Related Macular Degeneration","wAMD"],"enrollment":400,"completionDate":"2027-10"},{"nctId":"NCT06047379","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":["Diffuse Astrocytoma, IDH-Mutant","Glioblastoma, IDH-wildtype","Brain Metastases, Adult","Cervical Cancer","Colorectal Cancer","Esophageal Cancer","Esophageal Squamous Cell Carcinoma","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","Melanoma","Merkel Cell Carcinoma","Microsatellite Instability-High Solid Malignant Tumor","Mismatch Repair Deficient Solid Malignant Tumor","Microsatellite Instability-High Colorectal Cancer","Mismatch Repair Deficient Colorectal Cancer","Non-small Cell Lung Cancer","Renal Cell Carcinoma","Small Cell Lung Cancer","Squamous Cell Carcinoma","Urothelial Carcinoma"],"enrollment":134,"completionDate":"2027-08-31"},{"nctId":"NCT06075147","phase":"","title":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-02-15","conditions":["Visual Impairment","Neovascular Age-related Macular Degeneration (nAMD)","Diabetic Macula Edema (DME)"],"enrollment":2500,"completionDate":"2028-01-31"},{"nctId":"NCT05705258","phase":"","title":"A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-03-27","conditions":["Retinopathy of Prematurity","Newborns","Infants"],"enrollment":75,"completionDate":"2027-03-30"},{"nctId":"NCT06850922","phase":"PHASE1,PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-06-22","conditions":["Diabetic Macular Edema"],"enrollment":546,"completionDate":"2027-04-30"},{"nctId":"NCT04519619","phase":"","title":"Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)","status":"RECRUITING","sponsor":"Bayer","startDate":"2020-11-27","conditions":["Neovascular Glaucoma"],"enrollment":480,"completionDate":"2028-06-30"},{"nctId":"NCT07438119","phase":"PHASE4","title":"Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients","status":"NOT_YET_RECRUITING","sponsor":"Kun Liu","startDate":"2026-03-15","conditions":["Diabetic Macular Edema (DME)"],"enrollment":114,"completionDate":"2028-03-15"},{"nctId":"NCT07440225","phase":"PHASE2,PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-03-31","conditions":["Macular Degeneration","Age-Related Macular Degeneration","Choroidal Neovascularization","Wet Macular Degeneration"],"enrollment":960,"completionDate":"2028-06-30"},{"nctId":"NCT07434713","phase":"","title":"EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-07-14","conditions":["Age-Related Macular Degeneration (AMD)"],"enrollment":50,"completionDate":"2026-03-27"},{"nctId":"NCT07423429","phase":"","title":"Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-02","conditions":["Exudative Age-Related Macular Degeneration"],"enrollment":100,"completionDate":"2026-10"},{"nctId":"NCT07340372","phase":"","title":"Home Monitoring in eAMD Treatment","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-03","conditions":["Exudative Age-Related Macular Degeneration"],"enrollment":80,"completionDate":"2027-12"},{"nctId":"NCT07390253","phase":"","title":"Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vienna Institute for Research in Ocular Surgery","startDate":"2024-09-18","conditions":["Neovascular (Wet) Age-Related Macular Degeneration"],"enrollment":50,"completionDate":"2026-06-01"},{"nctId":"NCT05197270","phase":"PHASE1,PHASE2","title":"4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2021-12-09","conditions":["Neovascular (Wet) Age-Related Macular Degeneration"],"enrollment":215,"completionDate":"2031-01"},{"nctId":"NCT06550011","phase":"PHASE1,PHASE2","title":"Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avirmax Biopharma Inc","startDate":"2024-08-07","conditions":["Neovascular (Wet) AMD"],"enrollment":18,"completionDate":"2031-01-16"},{"nctId":"NCT07064759","phase":"PHASE3","title":"Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-07-22","conditions":["Neovascular Age-Related Macular Degeneration (nAMD)"],"enrollment":480,"completionDate":"2029-02"},{"nctId":"NCT04645212","phase":"","title":"Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2020-12-14","conditions":["Wet Age-related Macular Degeneration","Neovascular Age-related Macular Degeneration"],"enrollment":23,"completionDate":"2030-06-26"},{"nctId":"NCT07389980","phase":"PHASE3","title":"Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial","status":"RECRUITING","sponsor":"Yeungnam University College of Medicine","startDate":"2026-12-24","conditions":["Polypoidal Choroidal Vasculopathy","Polypoidal Choroidal Vasculopathy (PCV)"],"enrollment":50,"completionDate":"2028-12"},{"nctId":"NCT04663750","phase":"PHASE3","title":"Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2021-04-16","conditions":["Eye Diseases","Macular Degeneration, Wet","Sub-Macular Hemorrhage"],"enrollment":210,"completionDate":"2028-12"},{"nctId":"NCT04787341","phase":"PHASE2","title":"PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-12-15","conditions":["Colorectal Cancer"],"enrollment":214,"completionDate":"2026-03-31"},{"nctId":"NCT06321302","phase":"PHASE2","title":"A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-05-15","conditions":["Diabetic Retinopathy"],"enrollment":178,"completionDate":"2027-09-17"},{"nctId":"NCT07375901","phase":"NA","title":"the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2021-03-25","conditions":["AMD"],"enrollment":30,"completionDate":"2024-04-10"},{"nctId":"NCT07365371","phase":"PHASE4","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-01","conditions":["Polypoidal Choroidal Vasculopathy (PCV)","Neovascular Age Related Macular Degeneration (AMD)"],"enrollment":174,"completionDate":"2027-12-31"},{"nctId":"NCT03845049","phase":"PHASE3","title":"Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-07-03","conditions":["Macular Telangiectasia"],"enrollment":16,"completionDate":"2025-03-26"},{"nctId":"NCT07338097","phase":"NA","title":"Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema","status":"ENROLLING_BY_INVITATION","sponsor":"CMH Multan Institute of Medical Sciences","startDate":"2025-09-07","conditions":["Diabetic Macular Edema (DME)"],"enrollment":116,"completionDate":"2026-02-07"},{"nctId":"NCT05769153","phase":"PHASE1,PHASE2","title":"Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Alcon Research","startDate":"2023-12-06","conditions":["Neovascular Age-related Macular Degeneration (nAMD)"],"enrollment":140,"completionDate":"2027-10"},{"nctId":"NCT06422507","phase":"PHASE3","title":"A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-05-29","conditions":["Diabetic Macular Edema"],"enrollment":333,"completionDate":"2026-03-22"},{"nctId":"NCT04311606","phase":"PHASE2","title":"Anti-VEGF Therapy for Acute Thyroid Eye Disease","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2020-11-02","conditions":["Thyroid Eye Disease"],"enrollment":11,"completionDate":"2024-12-17"},{"nctId":"NCT07301775","phase":"PHASE4","title":"Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ahmad Zeeshan Jamil","startDate":"2026-01-01","conditions":["Diabetic Retinopathy (DR)","Diabetic Macular Edema (DME)","Cataract","Phacoemulfisication+IOL Implantation","Intravitreal Injection"],"enrollment":166,"completionDate":"2026-09-30"},{"nctId":"NCT05850520","phase":"PHASE3","title":"A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-05-15","conditions":["Macular Edema Secondary to Retinal Vein Occlusion"],"enrollment":892,"completionDate":"2025-05-27"},{"nctId":"NCT07213570","phase":"PHASE2","title":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-10-16","conditions":["Colorectal Cancer Metastatic"],"enrollment":60,"completionDate":"2027-04"},{"nctId":"NCT07235527","phase":"","title":"Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-11-20","conditions":["Age Related Macular Degeneration","Exudative Age-Related Macular Degeneration","Anti Vascular Endothelial Growth Factor"],"enrollment":54,"completionDate":"2026-08-20"},{"nctId":"NCT04932980","phase":"NA","title":"Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Berner Augenklinik","startDate":"2022-05-09","conditions":["Wet Age-related Macular Degeneration"],"enrollment":80,"completionDate":"2028-03"},{"nctId":"NCT06121180","phase":"PHASE2","title":"Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-04","conditions":["Metastatic Uveal Melanoma"],"enrollment":32,"completionDate":"2030-10-31"},{"nctId":"NCT03006081","phase":"PHASE2","title":"The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2016-04-14","conditions":["Diabetic Retinopathy"],"enrollment":38,"completionDate":"2018-08-30"},{"nctId":"NCT04101877","phase":"PHASE2","title":"The Sahlgrenska Anti-VEGF Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2020-09-03","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":402,"completionDate":"2027-05"},{"nctId":"NCT07205887","phase":"PHASE2","title":"A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO","status":"RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2025-09-12","conditions":["Neovascular Age-Related Macular Degeneration (NVAMD)","Branch Retinal Vein Occlusion (BRVO)"],"enrollment":160,"completionDate":"2028-06-30"},{"nctId":"NCT06856577","phase":"PHASE3","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2025-02-28","conditions":["Neovascular Age-Related Macular Degeneration (nAMD)","Wet AMD"],"enrollment":284,"completionDate":"2030-11-23"},{"nctId":"NCT03941587","phase":"NA","title":"Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment","status":"COMPLETED","sponsor":"Singapore National Eye Centre","startDate":"2021-02-01","conditions":["Polypoidal Choroidal Vasculopathy"],"enrollment":60,"completionDate":"2024-06-06"},{"nctId":"NCT02462889","phase":"PHASE2","title":"IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD","status":"COMPLETED","sponsor":"Jeffrey S Heier","startDate":"2015-06","conditions":["Age-Related Macular Degeneration"],"enrollment":128,"completionDate":"2019-03"},{"nctId":"NCT04522167","phase":"PHASE3","title":"Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Bioeq GmbH","startDate":"2020-07-21","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":434,"completionDate":"2023-05-18"},{"nctId":"NCT06591598","phase":"PHASE4","title":"A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-09-02","conditions":["Diabetic Macular Edema","Neovascular Age-related Macular Degeneration"],"enrollment":51,"completionDate":"2025-10-14"},{"nctId":"NCT06116890","phase":"PHASE2","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-01-31","conditions":["Neovascular Age-Related Macular Degeneration (nAMD)"],"enrollment":180,"completionDate":"2026-09-30"},{"nctId":"NCT06116916","phase":"PHASE2","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-01-09","conditions":["Diabetic Macular Edema (DME)"],"enrollment":150,"completionDate":"2026-09-30"},{"nctId":"NCT06769412","phase":"","title":"A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-07-01","conditions":["Retinal Vasculitis"],"enrollment":550000,"completionDate":"2025-09-01"},{"nctId":"NCT06556368","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kodiak Sciences Inc","startDate":"2024-08-23","conditions":["Wet Age-related Macular Degeneration"],"enrollment":675,"completionDate":"2027-08"},{"nctId":"NCT02159989","phase":"PHASE1","title":"Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-06-18","conditions":["Advanced Malignant Solid Neoplasm","Fibrolamellar Carcinoma","Metastatic Malignant Solid Neoplasm","Ovarian Carcinoma","Pancreatic Neuroendocrine Tumor","Recurrent Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm","Unresectable Solid Neoplasm"],"enrollment":83,"completionDate":"2024-01-29"},{"nctId":"NCT06491914","phase":"PHASE3","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-24","conditions":["Neovascular Age-Related Macular Degeneration","Diabetic Macular Edema"],"enrollment":1118,"completionDate":"2027-01-07"},{"nctId":"NCT05381948","phase":"PHASE2","title":"Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2022-06-30","conditions":["Wet Age-related Macular Degeneration"],"enrollment":161,"completionDate":"2024-04-24"},{"nctId":"NCT04015180","phase":"PHASE3","title":"Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-18","conditions":["Retinopathy of Prematurity (ROP)"],"enrollment":100,"completionDate":"2025-09-19"},{"nctId":"NCT07105228","phase":"","title":"Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-07-15","conditions":["Retinal Vasculitis"],"enrollment":290000,"completionDate":"2025-09-15"},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":["AMD","nAMD","Wet Age-related Macular Degeneration","wAMD","WetAMD","CNV"],"enrollment":660,"completionDate":"2027-11"},{"nctId":"NCT03712904","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2019-08-09","conditions":["Uveal Melanoma"],"enrollment":3,"completionDate":"2022-12-23"},{"nctId":"NCT05930561","phase":"PHASE2","title":"4D-150 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2023-08-09","conditions":["Diabetic Macular Edema","Diabetic Retinopathy"],"enrollment":72,"completionDate":"2029-02-28"},{"nctId":"NCT06985706","phase":"PHASE3","title":"Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns","status":"RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2025-05-19","conditions":["Severe Diabetic Macular Oedema"],"enrollment":264,"completionDate":"2028-11-30"},{"nctId":"NCT06850571","phase":"PHASE4","title":"Aflibercept and Bevacizumab for Diabetic Maculopathies","status":"RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-02-20","conditions":["Diabetic Maculopathy"],"enrollment":102,"completionDate":"2025-12-01"},{"nctId":"NCT04567550","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-11-20","conditions":["Diabetic Retinopathy (DR)","Center-Involved Diabetic Macular Edema (CI-DME)"],"enrollment":139,"completionDate":"2026-12"},{"nctId":"NCT03832179","phase":"PHASE4","title":"Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification","status":"COMPLETED","sponsor":"Bay Area Retina Associates","startDate":"2018-11-15","conditions":["Diabetic Macular Edema","Cataract"],"enrollment":16,"completionDate":"2024-03-30"},{"nctId":"NCT00532155","phase":"PHASE3","title":"A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":["Carcinoma","Non Small Cell Lung"],"enrollment":913,"completionDate":"2011-10"},{"nctId":"NCT04270747","phase":"PHASE3","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-06-22","conditions":["Neovascular (Wet) Age-related Macular Degeneration (AMD)"],"enrollment":576,"completionDate":"2023-01-30"},{"nctId":"NCT05511038","phase":"PHASE4","title":"A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-08-26","conditions":["Diabetic Macular Edema"],"enrollment":100,"completionDate":"2024-04-16"},{"nctId":"NCT06672536","phase":"PHASE1,PHASE2","title":"Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2024-11-26","conditions":["nAMD"],"enrollment":82,"completionDate":"2027-01-11"},{"nctId":"NCT03803631","phase":"","title":"CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2018-04-04","conditions":["AMD","Exudative Macular Degeneration"],"enrollment":49,"completionDate":"2021-11-15"},{"nctId":"NCT04423718","phase":"PHASE3","title":"Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-11","conditions":["Neovascular Age-Related Macular Degeneration"],"enrollment":1011,"completionDate":"2024-08-07"},{"nctId":"NCT05536973","phase":"PHASE2","title":"Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2022-08-23","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":69,"completionDate":"2028-08"},{"nctId":"NCT07129239","phase":"PHASE3","title":"High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)","status":"NOT_YET_RECRUITING","sponsor":"Clinique de Retine de l'est","startDate":"2025-08-20","conditions":["Wet Age-related Macular Degeneration (wAMD)"],"enrollment":180,"completionDate":"2027-02"},{"nctId":"NCT02556229","phase":"PHASE2","title":"Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-06","conditions":["Inflammatory Choroidal Neovascularization"],"enrollment":20,"completionDate":"2019-09"},{"nctId":"NCT04429503","phase":"PHASE2,PHASE3","title":"Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-06-29","conditions":["Diabetic Macular Edema","Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"],"enrollment":660,"completionDate":"2024-06-18"},{"nctId":"NCT02257502","phase":"PHASE2","title":"Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-07-06","conditions":["Idiopathic Choroidal Neovascularization"],"enrollment":20,"completionDate":"2019-07-11"},{"nctId":"NCT06011798","phase":"PHASE2","title":"Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)","status":"COMPLETED","sponsor":"Unity Biotechnology, Inc.","startDate":"2023-08-23","conditions":["Diabetic Macular Edema","Retinal Disease","Macular Edema","Diabetes Mellitus","Diabetic Retinopathy","Retinal Degeneration","Retinal Diseases","Eye Diseases","Edema"],"enrollment":52,"completionDate":"2025-04-08"},{"nctId":"NCT04757636","phase":"PHASE3","title":"OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":998,"completionDate":"2025-03-31"},{"nctId":"NCT07096713","phase":"NA","title":"Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-01-01","conditions":["Anti-VEGF Therapy"],"enrollment":38,"completionDate":"2024-06-01"},{"nctId":"NCT05891548","phase":"PHASE2","title":"Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Clearside Biomedical, Inc.","startDate":"2023-05-31","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":60,"completionDate":"2024-08-20"},{"nctId":"NCT03823287","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-02-19","conditions":["Wet Macular Degeneration"],"enrollment":671,"completionDate":"2022-01-18"},{"nctId":"NCT07074054","phase":"","title":"Aflibercept 8 mg for nAMD: Early Anatomical and Functional Changes","status":"COMPLETED","sponsor":"Federico II University","startDate":"2024-04-15","conditions":["Presence of Retinal Fluid","Changes in Macular Pigment Optical Density"],"enrollment":40,"completionDate":"2025-03-30"},{"nctId":"NCT03823300","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-03-11","conditions":["Wet Macular Degeneration"],"enrollment":658,"completionDate":"2022-01-07"},{"nctId":"NCT03622580","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-09-05","conditions":["Diabetic Macular Edema"],"enrollment":940,"completionDate":"2021-09-03"},{"nctId":"NCT03622593","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-10-09","conditions":["Diabetic Macular Edema"],"enrollment":951,"completionDate":"2023-05-31"},{"nctId":"NCT04418427","phase":"PHASE2","title":"ADVM-022 Intravitreal Gene Therapy for DME","status":"COMPLETED","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2020-05-28","conditions":["Diabetic Macular Edema","Diabetic Retinopathy"],"enrollment":36,"completionDate":"2023-06-14"},{"nctId":"NCT06662994","phase":"PHASE4","title":"High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy","status":"RECRUITING","sponsor":"Retina Consultants of Orange County","startDate":"2025-07-07","conditions":["Diabetic Macular Edema (DME)"],"enrollment":15,"completionDate":"2027-08-15"},{"nctId":"NCT06198413","phase":"PHASE1","title":"LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innostellar Biotherapeutics Co.,Ltd","startDate":"2023-02-27","conditions":["Neovascular Age-Related Macular Degeneration"],"enrollment":12,"completionDate":"2029-01"},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":["Metastatic Colorectal Cancer","MSI"],"enrollment":132,"completionDate":"2025-03-01"},{"nctId":"NCT06845163","phase":"PHASE2","title":"Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-02-08","conditions":["Diabetic Macular Edema","Center-involved Diabetic Macular Edema"],"enrollment":56,"completionDate":"2026-08"}],"_emaApprovals":[{"date":"2012-11-22","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravitreal","formulation":"Injection, Solution","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVITREAL","productName":"EYLEA"},{"form":"INJECTION, SOLUTION","route":"INTRAVITREAL","productName":"EYLEA HD"},{"form":"SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"ZALTRAP"}]},"crossReferences":{"NUI":"N0000184016","MMSL":"186189","NDDF":"014044","UNII":"15C2VL427D","VUID":"4031234","VANDF":"4031234","INN_ID":"8739","RXNORM":"1232150","UMLSCUI":"C1134659","chemblId":"CHEMBL1742982","ChEMBL_ID":"CHEMBL1742982","KEGG_DRUG":"D09574","DRUGBANK_ID":"DB08885","SNOMEDCT_US":"703840003","IUPHAR_LIGAND_ID":"6786","MESH_SUPPLEMENTAL_RECORD_UI":"C533178"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"INTRAVITREAL","company":"Regeneron Pharmaceuticals, Inc.","brandName":"EYLEA","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2011-","companyName":"Regeneron","relationship":"Original Developer"},{"period":"2020","companyName":"Bayer Yakuhin, Ltd","relationship":"PMDA Licensee"}],"pharmacokinetics":{"tmax":"2.9 days","halfLife":"Not specified","metabolism":"Aflibercept is a therapeutic protein expected to undergo elimination through target-mediated disposition via binding to free endogenous VEGF and metabolism via proteolysis. No drug metabolism studies have been conducted.","elimination":"Median time to reach non-quantifiable concentrations of free aflibercept in plasma following 8 mg intravitreal administration was 3.5 weeks. Elimination occurs through both target-mediated disposition and proteolysis.","bioavailability":"Not specified"},"publicationCount":4130,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:56:57.551363+00","atcClassification":{"source":"DrugCentral","atcCode":"L01XX44","allCodes":["L01XX44","S01LA05"]},"biosimilarFilings":[],"originalDeveloper":"Regeneron Pharmaceuticals","recentPublications":[{"date":"2026 Mar 24","pmid":"41905242","title":"Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629).","journal":"European journal of cancer (Oxford, England : 1990)"},{"date":"2026 Mar 28","pmid":"41904245","title":"Long term evolutions of hard exudates after anti-VEGF therapy for diabetic macular oedema.","journal":"Eye (London, England)"},{"date":"2026 Mar 28","pmid":"41903075","title":"Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.","journal":"Ophthalmology and therapy"},{"date":"2026 Mar 28","pmid":"41902887","title":"Use of Aflibercept 8 mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison.","journal":"Advances in therapy"},{"date":"2026 Mar 14","pmid":"41899134","title":"Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study.","journal":"Journal of clinical medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Regeneron","companyId":"regeneron","modality":"Recombinant protein","firstApprovalDate":"2011","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-08-03T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":"BLA125418"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-10-06T00:00:00.000Z","mah":"REGENERON PHARMACEUTICALS","brand_name_local":null,"application_number":"BLA125387"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-08-23T00:00:00.000Z","mah":"AMGEN INC","brand_name_local":null,"application_number":"BLA761298"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-17T00:00:00.000Z","mah":"FORMYCON AG","brand_name_local":null,"application_number":"BLA761378"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-11-19T00:00:00.000Z","mah":"REGENERON PHARMACEUTICALS","brand_name_local":null,"application_number":"BLA761355"},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":29,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:39:17.333437+00:00","fieldsConflicting":17,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}